Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Apparatus and methods to harvest biopolymer material, such as a mycological material comprising mycelia. The mycelia products that are harvested can be used in the food industry (for example, as an animal-based meat-substitute) and in other industries, such as textiles, packaging, and others. The present invention provides mycelial harvesting methods and systems that are repeatable and energy efficient, while providing high quality and quantity mycelium-based products.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: A propeller blade-tip flow isolator that can be used on a propeller, rotor, or wind turbine is provided. The propeller blade-tip flow isolator integrates with the blade at the outer radius and shields the propeller blade-tip boundary layer, reducing blade-tip vortices. A twist along the blade-tip chord further reduces or eliminates the blade-tip vortices that inherently occurs on the exposed blade tips during normal operations. Efficiency and performance are improved while noise and acoustic levels are reduced.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: The present invention relates to antagonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: A method and apparatus is disclosed for improving the MSI and MSI-X specifications by implementing an efficient delivery and clearing mechanism for interrupt conditions to increase performance between the driver and hardware/firmware interface while ensuring that no interrupts are lost in the process. In particular, an auto clear function is employed to eliminate the need for drivers in the host to send writes over the PCI-based bus to deassert and assert attention enable register bits and clear down attention register bits, and a fail safe mechanism is utilized to prevent lost interrupts.

Abstract: An at least partially moveable motor-vehicle outer skin is already known per se. An actuator formed of a polymer and/or ion-exchanging and/or other material exhibiting various conformations is provided so that the outer skin can be moved. This material is moveable as a result of physical or chemical effects. The novel outer skin of a motor vehicle requires no expensive tools for the production thereof. The flat section of the outer skin of the bodywork of a motor vehicle is made of a flexible material. A flexible material such as material for convertible top covers is easily moveable yet the surface thereof cannot be increased. This material is tensed at least over one part of the rib of the motor vehicle, e.g. over a space frame. At least one mechanically moveable adjusting element is provided beneath or on top of the edge of the section enabling the outer skin to be deformed. The adjusting element is normally connected to the rib of the motor vehicle.

Abstract: The use of a lipid in oxidised form for the manufacture of a medicament for therapeutically neutralising (i.e. reducing or substantially destroying the activity of) an organoboronate drug. The lipid may be an HDL hydroperoxide. The drug may be TRI 50c or a salt or prodrug thereof.

Abstract: An at least partially moveable motor-vehicle outer skin is already known per se. An actuator formed of a polymer and/or ion-exchanging and/or other material exhibiting various conformations is provided so that the outer skin can be moved. This material is moveable as a result of physical or chemical effects. The novel outer skin of a motor vehicle requires no expensive tools for the production thereof. The flat section of the outer skin of the bodywork of a motor vehicle is made of a flexible material. A flexible material such as material for convertible top covers is easily moveable yet the surface thereof cannot be increased. This material is tensed at least over one part of the rib of the motor vehicle, e.g. over a space frame. At least one mechanically moveable adjusting element is provided beneath or on top of the edge of the section enabling the outer skin to be deformed. The adjusting element is normally connected to the rib of the motor vehicle.

Abstract: In the past topical creams and lotions were mainly designed to be used to reduce pain and inflammation, and not necessarily to promote healing or regeneration. When existing remedies were designed to promote healing they were designed to do so by chemical mediation, e.g. by removing pain and/or blocking inflammatory produced substances produced in reaction to injury. The current invention is designed to operate entirely by a different mechanism of electrolytic induction. Using a composition of atomic metals suspended in a water based emulsion and suspension negative ion and polarity is induced in areas of the body where needed.